54 results match your criteria: "Mary M. Gooley Hemophilia Center[Affiliation]"
Haemophilia
October 2024
Mary M. Gooley Hemophilia Center, Rochester, New York, USA.
Haemophilia
July 2024
Department of Medicine, Mary M. Gooley Hemophilia Center, Rochester, New York, USA.
Introduction: Gastrointestinal (GI) bleeding events (BEs) in von Willebrand disease (VWD) are difficult to diagnose and often recurrent. Limited data from clinical trials has led to lack of consensus on treatment options.
Aim: Describe current treatments and outcomes for GI BEs in people with VWD.
Haemophilia
May 2024
Department of Hematology/Oncology, Mary M. Gooley Hemophilia Center, Rochester, New York, USA.
Expert Rev Hematol
May 2024
Hematology and Oncology, Rochester General Hospital, Rochester, NY, USA.
Background: Patients with p.C282Y homozygous (p.C282Y) mutations are more likely to develop hemochromatosis (HC) than p.
View Article and Find Full Text PDFJ Thromb Haemost
July 2024
Irish-Australian Blood Collaborative Network, Dublin, Ireland and Perth, Australia; National Coagulation Centre, St. James's Hospital, Dublin, Ireland; Irish Centre for Vascular Biology, School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
In many patients referred with significant bleeding phenotype, laboratory testing fails to define any hemostatic abnormalities. Clinical practice with respect to diagnosis and management of this patient cohort poses significant clinical challenges. We recommend that bleeding history in these patients should be objectively assessed using the International Society on Thrombosis and Haemostasis (ISTH) bleeding assessment tool.
View Article and Find Full Text PDFHaemophilia
January 2024
American Thrombosis Hemostasis Network, Rochester, New York, USA.
Introduction: Gene therapy is now a reality for individuals with haemophilia, yet little is known regarding the quality-of-life impact of factor correction. As few data exist, and recognizing the analogy to liver transplantation (OLTX), we identified OLTX+ and OLTX- men in the ATHNdataset to compare post-OLTX factor VIII and IX on quality of life (QoL) by Haem-A-QoL and PROMIS-29.
Methods: OLTX- were matched to OLTX+ by age, race, and haemophilia type and severity.
Expert Rev Hematol
March 2023
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Background: Excessive or abnormal mucocutaneous bleeding (MCB) may impact all aspects of the physical and psychosocial wellbeing of those who live with it (PWMCB). The evidence base for the optimal diagnosis and management of disorders such as inherited platelet disorders, hereditary hemorrhagic telangiectasia (HHT), hypermobility spectrum disorders (HSD), Ehlers-Danlos syndromes (EDS), and von Willebrand disease (VWD) remains thin with enormous potential for targeted research.
Research Design And Methods: National Hemophilia Foundation and American Thrombosis and Hemostasis Network initiated the development of a National Research Blueprint for Inherited Bleeding Disorders with extensive all-stakeholder consultations to identify the priorities of people with inherited bleeding disorders and those who care for them.
J Thromb Haemost
April 2023
Diagnostic Laboratories and Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA; Pediatric Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
Am J Obstet Gynecol
July 2023
Department of Obstetrics and Gynecology, University of California, San Diego, San Diego, CA; Department of Obstetrics and Gynecology, The George Washington University, Washington, DC.
Expert Rev Hematol
June 2023
Department of Hematology Oncology, Mary M. Gooley Hemophilia Center, Inc., The Rochester General Hospital, 14621, Rochester, NY, USA.
Introduction: Women and girls with bleeding disorders face multiple bleeding challenges throughout their life. The most significant morbidity and mortality are due to heavy menstrual bleeding and postpartum hemorrhage in their reproductive years. The ASH/ISTH/NHF/WFH 2021 guidelines on diagnosing and managing von Willebrand disease (VWD) provide several new updates.
View Article and Find Full Text PDFHaemophilia
March 2023
University of Southern California, Los Angeles, California, USA.
Objective: We assessed sociodemographic and clinical characteristics associated with depression and anxiety in individuals with Von Willebrand disease (VWD) aged ≥12 years.
Methods: The study collected data on patients' sociodemographic, joint problems and health-related quality of life (HRQoL) using EQ-5D-3L, 8-item patient health questionnaire for depression and 7-item Generalized Anxiety Disorder Questionnaire from participants in seven geographically diverse US haemophilia treatment centres.
Results: Analyses included 77 participants.
AJOG Glob Rep
November 2021
Rochester General Hospital, Rochester Regional Health, Rochester, NY (Drs Lee, Kouides, Bousquet, and Cabral).
Hemophagocytic lymphohystiocytosis is an extremely life-threatening immune deregulatory syndrome. It is characterized by pathologic activation of immune cells, leading to excessive cytokine production, multiorgan failure, and potentially, death. A 28-year-old primigravida at 32 weeks and 3 days of gestation presented with newly-diagnosed preeclampsia with severe features, fever, and fetal tachycardia.
View Article and Find Full Text PDFAm J Hematol
July 2022
Rochester General Hospital, Hematology and Oncology, Rochester, New York, USA.
Blood Adv
January 2022
Department of Pediatrics, Baylor College of Medicine, Houston, TX.
J Thromb Haemost
January 2022
Diagnostic Laboratories and Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA.
Background: The management of pregnant women with von Willebrand disease (VWD) is complex as physiological pregnancy-induced increases in plasma von Willebrand factor (VWF) may be blunted or absent. Women with VWD experience a heightened risk of postpartum hemorrhage (PPH) and special consideration must be given regarding neuraxial anesthesia (NA) and the need for prophylaxis at time of delivery. These challenges are compounded by a lack of robust evidence to guide clinical decision-making.
View Article and Find Full Text PDFAm J Hematol
November 2021
Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplant, Children's Hospital of Los Angeles, Los Angeles, California, USA.
Curr Opin Hematol
September 2021
University of Rochester School of Medicine and the Mary M. Gooley Hemophilia Center at Rochester General Hospital, Rochester, New York, USA.
Purpose Of Review: To summarize the recent literature related to female hemophilia A carriers with respect to prevalence in the population, the impact of baseline factor VIII levels and other influences on bleeding phenotype, and clinical management needs.
Recent Findings: Many female hemophilia A carriers are at risk for abnormal bleeding, yet they are underrecognized by healthcare providers and their bleeding symptoms are underreported. Low FVIII levels are consistently associated with clinically significant bleeding and correlate well with skewed X chromosome inactivation (XCI).
Hematol Oncol Clin North Am
December 2021
Mary M. Gooley Hemophilia Center, Rochester Regional Health, 1415 Portland Avenue, Rochester, NY 14621, USA.
Although rare clotting factor deficiencies primarily referred to as rare bleeding disorders (RBD), including factors II, V, VII, and X, make up ∼5% of all inherited bleeding disorders worldwide, each of these clotting factors play a critical role in the coagulation cascade. Incomplete bleeding evaluation or misinterpretation of laboratory studies can result in delayed diagnoses that ultimately affect patient outcomes. Bleeding manifestations can range from mild to severe, but the most common are mucocutaneous bleeding.
View Article and Find Full Text PDFJAMA Pediatr
October 2021
Mary M. Gooley Hemophilia Center, University of Rochester School of Medicine, Rochester, New York.
Importance: Recent studies have documented increased bleeding symptoms and related complications in patients with low von Willebrand factor (VWF), highlighting the clinical significance of this entity. Because children and adolescents with VWF deficiencies often present to primary care physicians with bleeding symptoms, physicians need to be aware of this condition for early detection.
Observations: Studies have found that children and adolescents with low VWF (VWF levels of 30-50 IU/dL) can present with clinically significant bleeding, including mucosal, menstrual, postsurgical, and posttraumatic bleeding, leading to complications such as anemia, iron deficiency, transfusion, hospitalization, and poor quality of life.
J Thromb Haemost
August 2021
Aflac Cancer and Blood Disorders, Emory University, Decatur, Georgia, USA.
Haemophilia
September 2021
Mary M. Gooley Hemophilia Center, Rochester, New York, USA.
Introduction: Reproductive tract bleeding (RTB) is an important outcome in menstruating females on anticoagulant therapy (AC). The diagnosis and management of AC-RTB in adolescent and young adult (AYA) females is unknown.
Aims: The aim of this study was to survey the contemporary patterns of diagnosis and management of AC-RTB in AYA females.
Haemophilia
July 2021
Clinical hematology and bone marrow transplant unit, Civil Service Hospital, Kathmandu, Nepal.
Haemophilia
July 2021
Division of Hematology/Oncology and Cellular Therapy, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park, NY, USA.